NEWS RELEASE

ADDITIONAL ANALYSES OF CRN04894 PRECLINICAL AND PHASE 1 RESULTS TO BE PRESENTED AT THE 10TH INTERNATIONAL CONGRESS OF NEUROENDOCRINOLOGY

2022-08-04

Contact:

Chas Schultz

VP, IR & Corporate Communications

cschultz@crinetics.com

(858) 450-6464

Investors / Media:

Corey Davis

LifeSci Advisors

cdavis@lifesciadvisors.com

(212) 915-2577

Aline Sherwood

Scienta Communications

asherwood@scientapr.com

(312) 238-8957

Source: Crinetics Pharmaceuticals, Inc.